| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| CBR1 | CBR3 | ENSP00000290349 | ENSP00000290354 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | 0.999 |
| CBR1 | HPGD | ENSP00000290349 | ENSP00000296522 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | 0.927 |
| CBR1 | PRXL2B | ENSP00000290349 | ENSP00000413218 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | Prostamide/prostaglandin F synthase; Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha) (By similarity). | 0.918 |
| CBR1 | PTGES | ENSP00000290349 | ENSP00000342385 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.939 |
| CBR1 | PTGES2 | ENSP00000290349 | ENSP00000345341 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | Prostaglandin E synthase 2 truncated form; Isomerase that catalyzes the conversion of PGH2 into the more stable prostaglandin E2 (PGE2). | 0.935 |
| CBR1 | PTGES3 | ENSP00000290349 | ENSP00000482075 | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | Prostaglandin E synthase 3; Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes. Facilitates HIF alpha proteins hydroxylation via interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90 pathway. | 0.933 |
| CBR3 | CBR1 | ENSP00000290354 | ENSP00000290349 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | 0.999 |
| CBR3 | HPGD | ENSP00000290354 | ENSP00000296522 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | 0.912 |
| CBR3 | PRXL2B | ENSP00000290354 | ENSP00000413218 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | Prostamide/prostaglandin F synthase; Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha) (By similarity). | 0.909 |
| CBR3 | PTGES | ENSP00000290354 | ENSP00000342385 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.910 |
| CBR3 | PTGES2 | ENSP00000290354 | ENSP00000345341 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | Prostaglandin E synthase 2 truncated form; Isomerase that catalyzes the conversion of PGH2 into the more stable prostaglandin E2 (PGE2). | 0.914 |
| CBR3 | PTGES3 | ENSP00000290354 | ENSP00000482075 | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | Prostaglandin E synthase 3; Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes. Facilitates HIF alpha proteins hydroxylation via interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90 pathway. | 0.916 |
| HPGD | CBR1 | ENSP00000296522 | ENSP00000290349 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Carbonyl reductase [NADPH] 1; NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2- alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S- nitrosoglutathione. | 0.927 |
| HPGD | CBR3 | ENSP00000296522 | ENSP00000290354 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Carbonyl reductase [NADPH] 3; Has low NADPH-dependent oxidoreductase activity towards 4- benzoylpyridine and menadione (in vitro). Belongs to the short-chain dehydrogenases/reductases (SDR) family. | 0.912 |
| HPGD | HSD11B2 | ENSP00000296522 | ENSP00000316786 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Corticosteroid 11-beta-dehydrogenase isozyme 2; Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids. | 0.801 |
| HPGD | PRXL2B | ENSP00000296522 | ENSP00000413218 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostamide/prostaglandin F synthase; Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha) (By similarity). | 0.923 |
| HPGD | PTGES | ENSP00000296522 | ENSP00000342385 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.971 |
| HPGD | PTGES2 | ENSP00000296522 | ENSP00000345341 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E synthase 2 truncated form; Isomerase that catalyzes the conversion of PGH2 into the more stable prostaglandin E2 (PGE2). | 0.960 |
| HPGD | PTGES3 | ENSP00000296522 | ENSP00000482075 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E synthase 3; Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes. Facilitates HIF alpha proteins hydroxylation via interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90 pathway. | 0.962 |
| HPGD | PTGR1 | ENSP00000296522 | ENSP00000385763 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin reductase 1; Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-oxo-PGE1, 15-oxo-PGE2 and 15-oxo-PGE2-alpha. Has no activity towards PGE1, PGE2 and PGE2-alpha (By similarity). Catalyzes the conversion of leukotriene B4 into its biologically less active metabolite, 12-oxo- leukotriene B4. This is an initial and key step of metabolic inactivation of leukotriene B4. | 0.963 |
